Références brochure de nos préparations pour nourrissons et de suite

‍

1. Swissmilk.ch, Schweizer Grasland und die Milch –das passt einfach, abgerufen am 22.11.2023.
2. Ulrike Gonder, Die Schweizer Milch – einnachhaltiges Lebensmittel, swissmilk.ch, Dezember 2023, abgerufen am 22.11.2023.
3. Schweizer Milchproduzenten SMP (2023),Landwirtschaftlich genutzte Fläche.
4. Swissmilk.ch, Die Mehrwerte der nachhaltigenSchweizer Milch, September 2023, abgerufen am 22.11.2023.
5. Swissmilk.ch, Nachhaltige Schweizer Milch,abgerufen am 20.11.2023.
6. Carnielli VP, et al. Structural positionand amount of palmitic acid in infant formulas: effects on fat, fatty acid, andmineral balance. J Pediatr Gastroenterol Nutr. 1996 Dec;23(5):553–60.
7. López-López A, et al. The influence of dietary palmitic acidtriacylglyceride position on the fatty acid, calcium and magnesium contents ofat term newborn faeces. Early Hum Dev. 2001 Nov;65 Suppl:S83-94.
8. Hageman J.H.J, et al. Comparison of bovinemilk fat and vegetable fat for infant formula: implications for infant health.International Dairy Journal 2019 92:37-49.
9. EFSA. Scientific Opinion on thesubstantiation of health claims related to calcium and maintenance of bones andteeth (ID 224, 230, 231, 354, 3099), muscle function and neurotransmission (ID226, 227, 230, 235), blood coagulation (ID 230, 236), energy-yieldingmetabolism (ID 234), function of digestive enzymes (ID 355), and maintenance ofnormal blood pressure (ID 225, 385, 1419) pursuant to Article 13(1) ofRegulation (EC) No 1924/2006. EFSA J [Internet]. [cited 2024 May 17];(2009;7(9):1210). Available from: https://data.europa.eu/doi/10.2903/j.efsa.2009.1210
10. Vandenplas Y, Alarcon P. Updatedalgorithms for managing frequent gastro-intestinal symptoms in infants. BenefMicrobes. 2015 Jan 1;6(2):199–208.
11. Gibson GR, et al. Expert consensusdocument: The International Scientific Association for Probiotics andPrebiotics (ISAPP) consensus statement on the definition and scope ofprebiotics. Nat Rev Gastroenterol Hepatol. 2017;14(8):491‐502.doi:10.1038/nrgastro.2017.75.
12. Flavio I, et al. Prebiotics in themanagement of pediatric gastrointestinal disorders: Position paper of theESPGHAN special interest group on gut microbiota and modifications. J PediatrGastroenterol Nutr. 2024;78:728–742.
13. Lasekan J, et al. Growth andGastrointestinal Tolerance in Healthy Term Infants Fed Milk-Based InfantFormula Supplemented with Five Human Milk Oligosaccharides (HMO): A RandomizedMulticenter Trial?, Nutrients 2022, 14 2625.
14. Bin Zhang, et al. Human milkoligosaccharides and infant gut microbiota: Molecular structures, utilizationstrategies and immune function. Carbohydr Polym [Internet]. Volume 276, 15January 2022, 118738. Available from:https://www.sciencedirect.com/science/article/abs/pii/S0144861721011255.
15. Ravindra Pal S, et al. Recentunderstanding of human milk oligosaccharides in establishing infant gutmicrobiome and roles in immune system. Food Res Int Vol 151 January 2022 110884[Internet]. Available from:https://www.sciencedirect.com/science/article/abs/pii/S0963996921007845.
16. Akkerman R, et al. Non-digestiblecarbohydrates in infant formula as substitution for human milk oligosaccharidefunctions: Effects on microbiota and gut maturation. Crit Rev Food Sci Nutr.2019;59(9):1486–97.
17. Dinleyici M, et al. Functional effects ofhuman milk oligosaccharides (HMOs). Gut Microbes. 2023;15(1):2186115.
18. Hill DR, et al. Multifunctional Benefits of PrevalentHMOs: Implications for Infant Health. Nutrients. 2021 Sep 25;13(10):3364.
19. Sprenger N, et al. Biology of human milkoligosaccharides: From basic science to clinical evidence. J Hum Nutr Diet OffJ Br Diet Assoc. 2022 Apr;35(2):280–99.
20. Meltem D, et al. Functional effects of human milkoligosaccharides (HMOs), Gut Microbes 2023, 15:1, 2186115, To link to thisarticle: https://doi.org/10.1080/19490976.2023.218611522.
21. Verordnung des EDI über Lebensmittel fürPersonen mit besonderem Ernährungsbedarf (VLBE) vom 16.Dezemberj2016 (Stand am 1. Februar 2024), Anhang 4
22. Bornet F, et al. Nutritional aspects ofshort-chain fructooligosaccharides: natural occurrence, chemistry, physiologyand health implications, Digestive and Liver Disease,Volume 34, Supplement2,2002,S111-S120.
23. Knol J, et al. Colon microflora in infantsfed formula with galacto- and fructo-oligosaccharides: more like breast-fedinfants, J PediatrGastroenterol Nutr, 2005 Jan;40(1):36-42.
24. Paineau D, et al. Effects of short-chainfructooligosaccharides on faecal bifidobacteria and specific immune response informula-fed term infants: a randomized, double-blind, placebo-controlled trial.J Nutr Sci Vitaminol (Tokyo). 2014;60(3):167-75. doi: 10.3177/jnsv.60.167.PMID: 25078372.28. Yap W.L.W. et al 2008.
25. Szilagyi A, Lactose — a potentialprebiotic. Aliment Pharmacol Ther. 2002 Sep;16(9):1591–602.
26. Paques M & Lindner C, Digestion,absorption, metabolism and physiological effects of lactose. In Lactose,Evolutionary role, Health effects, and Applications. eds: Academic Press,Elsevier, London UK, 2019.: https://doi.org/10.1016/B978-0-12-811720-0.00002-7.
27. Natividad JM, et al. Human MilkOligosaccharides and Lactose Differentially Affect Infant Gut Microbiota andIntestinal Barrier In Vitro. Nutrients. 2022 Jun 19;14(12):2546.
28. Zeevenhooven J, et al. Infant colic:mechanisms and management. Nat Rev Gastroenterol Hepatol. 2018Aug;15(8):479–96.
29. Kanabar D, et al. Improvement of symptomsin infant colic following reduction of lactose load with lactase. J Hum NutrDiet. 2001 Oct;14(5):359–63.
30. Infante D. Dietary treatment of coliccaused by excess gas in infants: Biochemical evidence. World J Gastroenterol.2011;17(16):2104.
31. EFSA. Scientific Opinion on the essentialcomposition of infant and follow-on formulae. EFSA J [Internet]. 2022 Oct 3[cited 2022 Oct 3];(2014;12(7):3760). Available from: https://data.europa.eu/doi/10.2903/j.efsa.2014.3760.
32. EFSA. Animal protein and bone growth. EFSAJ. 2008;(2008; 858:1-10).
33. Koletzko B, et al. High protein intake inyoung children and increased weight gain and obesity risk. Am J Clin Nutr. 2016Feb;103(2):303–4.
34. Turck D, et al. Adequacy and safety of aninfant formula with a protein/energy ratio of 1.8 g/100 kcal and enhancedprotein efficiency for term infants during the first 4 months of life. JPediatr Gastroenterol Nutr. 2006 Sep;43(3):364–71.
35. Pietrobelli A, Agosti M, Nutrition in theFirst 1000 Days: Ten Practices to Minimize Obesity Emerging from PublishedScience. Int J Environ Res Public Health. 2017 Dec;14(12):1491.
36. Donovan S. Human Milk Proteins:Composition and Physiological Significance. Nestle Nutr Inst Workshop Ser. 2019.
37. Kunz C, Lönnerdal B,. Re-evaluation of thewhey protein/casein ratio of human milk. Acta Paediatr 1992 Feb;81(2):107-12.doi: 10.1111/j.1651-2227.1992.tb12184.x.
38. Walzem RL, et al. Whey Components:Millennia of Evolution Create Functionalities for Mammalian Nutrition: What WeKnow and What We May Be Overlooking. Crit Rev Food Sci Nutr. 2002;42(4):353–75.
39. Wang X, et al. Gastric digestion of milkprotein ingredients: Study using an in vitro dynamic model. J Dairy Sci. 2018Aug;101(8):6842–52.
40. Yaron S, et al. Effect of High β‐PalmitateContent in Infant Formula on the Intestinal Microbiota of Term Infants. JPediatr Gastroenterol Nutr. 2013 Apr;56(4):376–81.
41. Yao M, et al. Effects of term infantformulas containing high sn-2 palmitate with and without oligofructose on stoolcomposition, stool characteristics, and bifidogenicity. J Pediatr GastroenterolNutr. 2014 Oct;59(4):440–8.
42. EFSA. Scientific substantiation of ahealth claim related to docosahexaenoic acid (DHA) and arachidonic acid (ARA)and visual development pursuant to Article14 of Regulation (EC) No 1924/20061Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies.EFSA J. (2009; 941:2-14).
43. Forsyth S, et al. The importance ofdietary DHA and ARA in early life: a public health perspective. Proc Nutr Soc.2017 Nov;76(4):568–73.
44. Koletzko B, et al. Should formula forinfants provide arachidonic acid along with DHA? A position paper of theEuropean Academy of Paediatrics and the Child Health Foundation. Am J ClinNutr. 2020 Jan;111(1):10–6.
45. Gibson RA, et al. Conversion of linoleicacid and alpha‐linolenic acid to long‐chain polyunsaturated fatty acids(LCPUFAs), with a focus on pregnancy, lactation and the first 2 years of life.Matern Child Nutr. 2011 Apr;7(s2):17–26.
46. Makrides M, et al. A randomized trial ofdifferent ratios of linoleic to alpha-linolenic acid in the diet of terminfants: effects on visual function and growth. Am J Clin Nutr. 2000Jan;71(1):120–9.
47. EFSA. Scientific substantiation of ahealth claim related to α-linolenic acid and linoleic acid and growth anddevelopment of children pursuant to Article 14 of Regulation (EC) No1924/20061. EFSA J. (2008; 783:1-9).
48. Salvatore S, et al. Thickened infantformula: What to know. Nutrition. 2018 May;49:51–6.
49. González-Bermúdez CA, et al. Effects ofdifferent thickening agents on infant gut microbiota. Food Funct.2018;9(3):1768–78.
50. González-Bermúdez CA, et al. Effect ofadding different thickening agents on the viscosity properties and in vitromineral availability of infant formula. Food Chem. 2014 Sep;159:5–11.
51. Singhal A, et al. Dietary Nucleotides andEarly Growth in Formula-Fed Infants: A Randomized Controlled Trial. Pediatrics.2010 Oct 1;126(4):e946–53.
52. Schaller JP, et al. Conditionallyessential nutrients shown to enhance immune function and reduce diarrhealdisease in infants. Semin Fetal Neonatal Med. 2007 Feb;12(1):35–44.
53. EFSA Panel on Dietetic Products, Nutritionand Allergies. Scientific Opinion on the substantiation of health claimsrelated to choline and contribution to normal lipid metabolism (ID 3186),maintenance of normal liver function (ID 1501), contribution to normalhomocysteine metabolism (ID 3090), maintenance of normal neurological function(ID 1502), contribution to normal cognitive function (ID 1502), and brain andneurological development (ID 1503) pursuant to Article 13(1) of Regulation (EC)No 1924/2006. EFSA J [Internet]. [cited 2024 May 22];(2011;9(4):2056).Available from: https://data.europa.eu/doi/10.2903/j.efsa.2011.2056.
54. Dietary Reference Values for choline, EFSA[Internet]. 2022 [cited 2022 Dec 13]. Available from:https://www.efsa.europa.eu/en/efsajournal/pub/4484.
55. Mun JG, et al. Choline and DHA in Maternaland Infant Nutrition: Synergistic Implications in Brain and Eye Health.Nutrients. 2019 May 21;11(5):1125.
56. Ripps H, et al. A “very essential” aminoacid. Mol Vis. 2012.
57. Kilb W, Fukuda A. Taurine as an EssentialNeuromodulator during Perinatal Cortical Development. Front Cell Neurosci. 2017Oct 24;11:328.
58. Almeida CC, et al. Bioactive Compounds inInfant Formula and Their Effects on Infant Nutrition and Health: A SystematicLiterature Review. Spigno G, editor. Int J Food Sci. 2021 May 14;2021:1–31.
59. Paquette AF, et al. The human milkcomponent myo -inositol promotes neuronal connectivity. Proc Natl Acad Sci.2023 Jul 25;120(30):e2221413120.
60. Pekala J, et al. L-Carnitine - MetabolicFunctions and Meaning in Humans Life. Curr Drug Metab. 2011 Sep 1;12(7):667–78.
61. Office of Dietary Supplements - Carnitine:The Science Behind a Conditionally Essential Nutrient - Conference Summary[Internet]. 2022 [cited 2022 Nov 10]. Available from: https://ods.od.nih.gov/News/Carnitine_Conference_Summary.aspx.
62. EFSA Panel on Dietetic Products, Nutritionand Allergies. Scientific Opinion on health claims already evaluated (ID 215,568, 674, 712, 1398, 1633, 1974, 4191, 4192, 4193, 4236, 4335, 4698, 4704)pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J [Internet].[cited 2024 May 24];(2011;9(6):2203). Available from:https://data.europa.eu/doi/10.2903/j.efsa.2011.2203.
63. EFSA Panel on Dietetic Products, Nutritionand Allergies. Scientific Opinion on the substantiation of health claimsrelated to vitamin D and maintenance of bone and teeth (ID 150, 151, 158),absorption and utilisation of calcium and phosphorus and maintenance of normalblood calcium concentrations (ID 152, 157), cell division (ID 153), and thyroidfunction (ID 156) pursuant to Article 13(1) of Regulation (EC) No 1924/2006.EFSA J [Internet]. [cited 2024 May 24];(2009; 7(9):1227). Available from:https://data.europa.eu/doi/10.2903/j.efsa.2009.1227.
64. EFSA. Vitamin D and bone growth. EFSA J.2008 827, 1-10.
65. EFSA Panel on Dietetic Products, Nutritionand Allergies (NDA). Scientific Opinion on the substantiation of health claimsrelated to vitamin D and normal function of the immune system and inflammatoryresponse (ID 154, 159), maintenance of normal muscle function (ID 155) andmaintenance of normal cardiovascular function (ID 159) pursuant to Article13(1) of Regulation (EC) No 1924/2006. EFSA J [Internet]. 2010 Feb [cited 2024May 24];8(2). Available from: https://data.europa.eu/doi/10.2903/j.efsa.2010.1468.
66. EFSA Panel on Dietetic Products, Nutritionand Allergies. Scientific Opinion on the substantiation of health claimsrelated to vitamin C and reduction of tiredness and fatigue (ID 139, 2622),contribution to normal psychological functions (ID 140), regeneration of thereduced form of vitamin E (ID 202), contribution to normal energy-yieldingmetabolism (ID 2334, 3196), maintenance of the normal function of the immunesystem (ID 4321) and protection of DNA, proteins and lipids from oxidativedamage (ID 3331) pursuant to Article 13(1) of Regulation (EC) No 1924/2006.EFSA J [Internet]. [cited 2024 May 24];(2010; 8(10):1815). Available from:https://data.europa.eu/doi/10.2903/j.efsa.2010.1815.
67. EFSA Panel on Dietetic Products, Nutritionand Allergies. Scientific Opinion on the substantiation of health claimsrelated to vitamin C and protection of DNA, proteins and lipids from oxidativedamage (ID 129, 138, 143, 148), antioxidant function of lutein (ID 146),maintenance of vision (ID 141, 142), collagen formation (ID 130, 131, 136, 137,149), function of the nervous system (ID 133), function of the immune system(ID 134), function of the immune system during and after extreme physicalexercise (ID 144), non-haem iron absorption (ID 132, 147), energy-yieldingmetabolism (ID 135), and relief in case of irritation in the upper respiratorytract (ID 1714, 1715) pursuant to Article 13(1) of Regulation (EC) No1924/2006. EFSA J [Internet]. [cited 2024 May 24];(2009; 7(9):1226). Availablefrom: https://data.europa.eu/doi/10.2903/j.efsa.2009.1226.
68. EFSA Panel on Dietetic Products, Nutritionand Allergies. Scientific substantiation of a health claim related to calciumand bone  growth pursuant to Article 14of Regulation (EC) No 1924/2006. EFSA J. 2008 826:1-11.
69. Scientific Opinion on the Substantiationof a health claim related to Iron and cognitive development of childrenpursuant to Article 14 of Regulation (EC) No 1924/2006. EFSA J [Internet].[cited 2024 May 24];(2009; 7(11):1360). Available from: https://data.europa.eu/doi/10.2903/j.efsa.2009.1360.
70. Scientific Opinion on the substantiationof health claims related to iron and formation of red blood cells andhaemoglobin (ID 249, ID 1589), oxygen transport (ID 250, ID 254, ID 256),energy-yielding metabolism (ID 251, ID 1589), function of the immune system (ID252, ID 259), cognitive function (ID 253) and cell division (ID 368) pursuantto Article 13(1) of Regulation (EC) No 1924/2006. EFSA J [Internet]. [cited2024 May 24];(2009; 7(9):1215). Available from:https://data.europa.eu/doi/10.2903/j.efsa.2009.1215.
71. Scientific Opinion on the substantiation of health claims related toiron and formation of red blood cells and haemoglobin (ID 374, 2889), oxygentransport (ID 255), contribution to normal energy-yielding metabolism (ID 255),reduction of tiredness and fatigue (ID 255, 374, 2889), biotransformation ofxenobiotic substances (ID 258), and “activity of heart, liver and muscles” (ID397) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. EFSA J[Internet]. [cited 2024 May 24];(2010; 8(10):1740). Available from:https://data.europa.eu/doi/10.2903/j.efsa.2010.1740